Index

absorbed dose, for CT, 31, 32
acute coronary syndrome, 96
adenosine/dipyridamole stress perfusion, 70
adverse effects
of CAD diagnosis, 152
of gadolinium, 21–22
of iodine agents, 26–27
after SPECT, 152
after stress ECG, 152
AEF see atrioesophageal fistula
Agatston score, 81
akinesis, 159
alopecia, as radiation side effect, 34
amyloidosis, cardiac involvement in, 178
aneurism, coronary artery, 232
angiography
atherosclerosis and, 82–85
CAD diagnosis with, 57
catheters, 48–49
chest pain and, 99–100
dose for, 33
serial, 260
see also computed tomography
angiography; CT subtraction angiography; magnetic resonance coronary angiography
angioplasty, 339
animal models
atherosclerosis in, 270
perfusion heterogeneity in, 114
annuloplasty rings, 47
anterior interventricular vein, 213
aortic stenosis
case example of, 192
CMR for, 186
noncardiac surgery and, 186
stress ECG for, 186
"area at risk," 296
arterial remodeling, 262–63
serial angiography of, 260
arterial stenosis
atherosclerosis imaging and, 259–61
coronary, 233–35
degree of, 259
episodic occurrence of, 261
artery
coronary, 87–88
aneurism of, 232
anomalous, 232
CABG and, 235–36
contrast in, 231–32
ECG gating for, 87
Kawasaki’s disease and, 232
MRI for, 87
normal, 232
operator experience in, 237
plaques and, 237
stenosis of, 233–35
stents and, 236
peripheral, 85
atheroma
lipid-rich, 265
nonocclusive, 261
atherosclerosis
in animal models, 270
biomarkers for, 271
coronary angiographic, 82–85
coronary arteries and, 87–88
endothelial activation and, 266
lifetime risk calculators for, 252
MDCT for, 80–85
MRI for, 85
peripheral arteries and, 85
plaque and
morphology of, 86–87
quantification and, 85
research on, 270–71
statins for, 270
in vivo experiments on, 270
atherosclerosis imaging, 88–89
arterial stenosis and, 259–61
for asymptomatic patients, 244–45,
behavior modification with, 245, 247, 248
clinicians’ perspectives on, 269
cost of, 250, 252
heart disease prediction with, 244
latent cardiovascular risk and, 244
patient management with
emergency room, 250
invasive testing and, 249–50
lifetime risk calculators and, 252
medication adherence and, 249
medication provision in, 247–48
noncalcified plaque and, 252
prognosis with, 251
valvular heart surgery and, 250
prevention with
primary, 271–72
secondary, 272–73
revascularization and, 260
statements on, 246
atrial fibrillation
AEF and, 209
CMR for, 203
CT for, 203
electrophysiology, 202
pathophysiology of, 202–3
prevalence of, 202
pulmonary vein stenosis and, 207
atrioesophageal fistula (AEF), 209
attenuation artifacts, 158
automatic pitch control, 39–40
barium enema, 33
behavior modification, 245, 247, 248
bicuspid aortic valve, 193
biomarkers, for atherosclerosis, 271
bismuth-based breast shield, 40
blood count, 33
burns, 34
CAD see coronary artery bypass grafting
calcification, coronary
on EBCT, 58
on MDCT, 58
calcium, coronary
atherosclerosis imaging and, 245, 247
dose reduction for, 36
mass quantification of, 82
morbid event prediction with, 264
calcium score, 80–82, 264
carcinogens, 34
cardiac catheterization, 57
cardiac resynchronization
CMR for, 212–13
conduction delay with, 331, 333
pacemakers for, 211–12
cardiomyopathy
arrhythmogenic right-ventricular,
177–78
dilated, 175–76
hypertrophic, 176
iron overload, 179
ischemic, 170, 172–73
nonischemic, 175
restrictive, 178
cardiovascular magnetic resonance (CMR)
adequacy of, 163
annuloplasty rings as, 47
for aortic stenosis, 186
for atrial fibrillation, 203
benefits of, 214
for CAD, 97–99
for cardiac resynchronization, 212–13
chest pain evaluation with
diagnostic performance of, 98
ischemic burden and, 98
reduced perfusion in, 97
cine images with, 219–21
contraindications for, 70
contrast agents for, 300–301
epicardial wires as, 46
flow visibility of, 219–21
heart failure and
arrhythmogenic right-ventricular
cardiomyopathy and, 177–78
dilated cardiomyopathy and, 175–76
hyperenhancement patterns in, 172
hypertrophic cardiomyopathy and, 176
infiltrative disease and, 178–79
iron overload cardiomyopathy and, 179
left apical ballooning and, 179
LGE and, 171
LV function and, 169
myocardial viability and, 173–74
myocarditis and, 175
nonischemic cardiomyopathy and, 175
restrictive cardiomyopathy and, 178
RV function and, 169
implanted devices’ interactions with
catheters as, 48–49
coils as, 48
coronary stents as, 47–48
ECG leads as, 46
electrical currents in, 45
electromagnetic interference with, 46
filters as, 48
guidewires as, 48–49
ICD as, 49
intraventricular balloon pumps as, 51
magnetism and, 44
movement of, 44
pacemakers as, 49, 50
septal defect closure devices as, 48
stenal wires as, 46
ventricular assist devices as, 51
interventional
applications of, 339
catheters for, 337–39
cell delivery with, 340
diagnostic catheterization with, 339
electrophysiology with, 341
eンドゴraft therapy with, 339–40
laboratory equipment for, 336–37
stenting with, 339–40
vascular angioplasty with, 339
limitations of, 191, 214
myocardial infarction and, 295
"area at risk" with, 296
edema during, 298–99
microvascular obstruction and,
299–300
"no-reflow" phenomenon and,
299–300
peri-infarct zone with, 296–98
revascularization and, 299
size of, 297
prosthetic valves as, 47
for pulmonary vein stenosis, 207
safety of, 43
patient condition and, 44, 45
protocol for, 50
see also dobutamine stress CMR;
magnetic resonance imaging;
perfusion CMR
carotid endarterectomy, 195
cataracts, 33
catheters
angiography, 48–49
CAD diagnosis with, 57
CMR interactions with, 48–49
diagnostic, 339
electrophysiology, 48–49
for interventional CMR, 337–39
stress testing and, 150
Swan-Genz, 49
cell delivery
with interventional CMR, 340
stem, 283–84
cellular labeling
contrast agents for, 280–81
fluorescence microscopy with,
278
hybrid, 280, 284
inversion recovery and, 282
limitations of, 286–87, 289
methods for, 281, 283
microencapsulation for, 280
noninvasive imaging with, 279
reporter gene imaging for, 279–80
strategies for, 278
chemical shift, 11
chest pain
acute, 71
angiography for
diagnostic accuracy of, 99
ischemic magnitude and, 99–100
CAD and
acute coronary syndrome and, 96
CABG and, 96
CMR for, 97–99
chest pain (cont.)
CT for, 99–100
PCI and, 96
CMR for
  diagnostic performance of, 98
  ischemic burden and, 98
  reduced perfusion in, 97
myocardial infarction and, 58
myocardial necrosis, 66
resting function and, 66
stable, 58
CIN see contrast-enhanced nephropathy cine images
  with CMR, 219–21
  with CT subtraction angiography, 321
CMR see cardiovascular magnetic resonance
coils, CMR interactions with, 48
collagen-degrading enzymes, 261
collagen metabolism, 263
computed tomography (CT), 3–5
  advances in, 318, 319
  for atrial fibrillation, 203
  automatic pitch control and, 39–40
  benefits of, 214
  for CAD, 99–100
  cone-beam, 321
  contrast agents for, 6–7, 23–28
  dosage for, 26
dose for
  absorbed, 31, 32
  effective, 31, 32
  equivalent, 32
  index volume, 32
  limiting scan coverage and, 35–36
  physical aspects of, 31
  reduction of, 34–35
  risks of, 33–34
dose length product of, 32
dual-source, 320
ECG-gated, 5, 6, 322
ECG pulsing for, 37, 38–39
for heart failure, 179
image display in, 7, 9
image reconstruction in, 5–6
kilovoltage and, 40
of left atrial appendage, 207
limitations of, 214
modes of, 321
multi-detector, 22
multirow, 321–22
noise based approach to, 40–41
non-contrast, 22
prospective ECG triggering for, 36–37, 39
protocol for
  patient position in, 7
  typical, 8
shielding and, 40
temporal resolution of, 5, 318–20
timing of, 26
tube current modulation for, 37, 38, 40
volume coverage of, 320–23
whole organ perfusion imaging with, 322
see also electron beam CT; multidetector CT; single photon emission computed tomography
computed tomography angiography (CTA)
  adequacy of, 163
  chest pain evaluation with
diagnostic accuracy of, 99
ischemic magnitude and, 99–100
coronary artery with
  aneurism of, 232
  anomalous, 232
  CABG and, 235–36
  contrast in, 231–32
Kawasaki’s disease and, 232
  normal, 232
  operator experience in, 237
  plaques and, 237
  stenosis of, 233–35
  stents and, 236
development of, 318
dose reduction in, 324
evaluation of, 160
ischemia and, 162–63
limitations of, 191
motion artifact suppression by, 230–31
for noncardiac surgery, 189, 191
spatial resolution of, 229–30
validation of, 159
cone-beam CT, 321
congenital heart disease
  assessment of, 187
  case example of, 193
  hypertension and, 187
noninvasive testing for, 186, 188
risk factors for, 187
unrestricted shunts and, 188
congestive heart failure, 187
conjoined veins, 203
contrast agents
for cellular labeling, 280–81
for CT, 6–7, 23–28
gadolinium as, 17–22
"hot spot," 281
iodine as, 23–28
manganese as, 19, 300–301
for MRI, 17–22
paramagnetic, 281
superparamagnetic, 281
contrast-enhanced nephropathy (CIN),
27–28
coronary artery
aneurism of, 232
anomalous, 232
CABG and, 235–36
contrast in, 231–32
Kawasaki's disease and, 232
normal, 232
operator experience in, 237
plaques and, 237
stenosis of, 233–35
stents and, 236
coronary artery bypass grafting (CABG)
CAD and, 96
LGE and, 171
LVEF dysfunction and, 111
as prior revascularization, 100–102
visualization and, 235–36
coronary artery calcium see calcium, coronary
coronary artery disease (CAD)
chest pain and
acute coronary syndrome and, 96
CABG and, 96
CMR for, 97–99
CT for, 99–100
PCI and, 96
diagnosis of
adverse events after, 152
anatomic validation of, 148–50
cardiac catheterization for, 57
coronary angiography for, 57
dobutamine stress CMR for, 57
EBCT for, 58
hybrid imaging for, 139
limitations of, 150
MDCT for, 58–60, 71–72
meta analysis and, 151
MRCA for, 60, 61
myocardial perfusion CMR for, 64, 65, 66, 72
noninvasive approaches' relative accuracy of, 66, 67, 68
normalcy rate and, 151
outcome-based, 151–52
quality evaluation process with, 149
test abnormalities and, 152–54
hybrid imaging for, 139, 141
prognosis assessment with, 105–6
revascularization and
prior CABG as, 100–102
prior stenting as, 102, 104–5
vein grafts as, 103
risk and, 152–54
stable chest pain and, 58
stepwise approach to, 68–71
valve disease and, 73
coronary vein, 213
cost
of atherosclerosis imaging, 250, 252
of heart failure, 211
c-reactive protein, 271
CTA see computed tomography angiography
delayed-enhancement CMR (DE-CMR)
infarction imaging with, 20
LVEF viability testing with, 115, 116, 117–18, 119, 121
DENSE see displacement-encoding of stimulated echo
diastole, 222
displacement-encoding of stimulated echo (DENSE), 330, 331, 334
dobutamine stress CMR
CAD diagnosis with, 62, 63–64
contraindications for, 70
myocardial segment visualization and, 174
dobutamine stress CMR (cont.)
noncardiac surgery and, 189, 190
preoperative risk assessment with, 194
Doppler flow measurement, 221
Doppler ultrasound, 223

dose, radiation
for angiography, 33
for barium enema, 33
CT
absorbed, 31, 32
effective, 31, 32
equivalent, 32
index volume, 32
limiting scan coverage and, 35–36
physical aspects of, 31
reduction of, 34–35
risks of, 33–34
CTA, 324
CT subtraction angiography, 323
from CT subtraction angiography, 323
of gadolinium, 19–20
of iodine agents, 26
legal limit of, 33
length product, 32
natural background, 33
of natural background radiation, 33
risks of
deterministic, 33
stochastic, 34

EBCT see electron beam CT
ECG see electrocardiogram
echo train, 308
edema, during myocardial infarction, 298–99
effective dose, for CT, 31, 32
elastin-degrading enzymes, 261
elastin metabolism, 263
electrical currents, implanted devices with, 45
electrocardiogram (ECG)
gated imaging with
coronary arteries and, 87
CT, 5–6
MRI, 14
non-, 322
leads of, 46
prospective triggering with, 36–37, 39
pulsing, 37, 38–39
see also stress ECG
electromagnetic interference, with implanted devices, 46
electron beam CT (EBCT)
CAD diagnosis with, 58
coronary calcification on, 58
electrophysiology
atrial fibrillation, 202
catheters, 48–49
guidance of, 209
with interventional CMR, 341
emergency room, patient management in, 250
endograft therapy, 339–40
endothelial activation
in atherogenesis, 266
leukocyte adhesion molecules and, 267
markers of, 267
end-stage renal disease, 194
epicardial wires, CMR interactions with, 46
erythema, as radiation side effect, 34
esophagus anatomy, 209, 210–11
excitation, selective, 13–14
exposure, 32
FDG see fluorodeoxyglucose
Feldkamp algorithm, 321
fibrosis
plexiform, 176
progressive interstitial, 175
filters, CMR interactions with, 48
flip angle, 10
flow
MRI measurement of, 312
multidirectional nature of, 223
paths of, 222
visibility of, 219–21
volume, 224–26
flow-limiting disease, 143
fluorodeoxyglucose (FDG)
macrophages and, 268
plaque and, 144
fluoroscopy, 209, 278
Fontan circulation, 187
free pulmonary regurgitation, 225
frequency, resonance, 11
functional recovery, from LVEF dysfunction, 127–29
gadolinium
adverse effects of, 21–22
cellular labeling with, 280–81
commercially available, 18
dosage for, 19–20
infarct imaging with, 20
myocardial perfusion imaging with, 19–20
properties of, 17, 19
see also late gadolinium enhancement
gantry rotation times, 318–19
gene imaging, 279–80
glycolytic pathways, 268
Greenfield filters, 48
grid tags, 329
guidewires, CMR interactions with, 48–49
hair loss, as radiation side effect, 34
hazard function, 156
heart
flow through
multidirectional nature of, 223
paths of, 222
volume of, 224–26
valvular surgery on, 250
heart disease
myocardial mechanics and, 333
prediction of, 244
heart failure
arrhythmogenic right-ventricular cardiomyopathy and, 177–78
cardiac resynchronization for, 211–13
congestive, 187
costs of, 211
CT for, 179
decompensated, 187
dilated cardiomyopathy and, 175–76
guidelines for, 169
hyperenhanecment patterns in, 172
hypertrophic cardiomyopathy and, 176
infiltrative disease and, 178–79
iron overload cardiomyopathy and, 179
ischemic cardiomyopathy and, 170, 172–73
left apical ballooning and, 179
LGE, 171
LV function and, 169
myocardial viability and, 173–74
myocarditis and, 175
nonischemic cardiomyopathy and, 175
pathophysiology of, 169
prevalence of, 211
restrictive cardiomyopathy and, 178
RV function and, 169
high field strength MRI
cardiac function and, 305–8
challenges of, 305
coronary imaging with, 310–12
echo train of, 308
flow assessment with, 312
inversion recovery and, 307
ischemia imaging with, 308–10
myocardial infarction imaging with, 308–10
myocardial perfusion imaging with, 310
myocardial tagging with, 307
parallel imaging with, 306
signal to noise ration of, 305
spatial resolution of, 305
high-sensitivity assay, 271
hybrid imaging
CAD diagnosis with, 139
CAD prognosis with, 139, 141
flow-limiting disease and, 143
molecular imaging and, 144
patient management with, 142–43
hyperenhancement patterns, 172
hyperenhancement patterns, in cardiomyopathy, 172
hypertension, 187
ICD see implantable cardioverter defibrillator
implantable cardioverter defibrillator (ICD), 49
index volume dose, for CT, 32
infiltrative disease, 178–79
inflammation, with plaque, 263
intra-aortic balloon pump, CMR interactions with, 51
invasive intramuscular ultrasound (IVUS), 159
inversion recovery
cellular labeling and, 282
high field strength MRI and, 307
iodine agents
adverse effects of, 26–27
commercially available, 24–25
delivery of, 23, 25
dosage with, 26
properties of, 23
timing with, 26
“triple rule-out” protocol for, 26
ischemia
  chest pain evaluation and, 98–100
  high field strength MRI for, 308–10
  revascularization and, 162–63
ischemic burden, 98
ischemic magnitude, 99–100
ischemic revascularization, 162
IVUS see invasive intramuscular ultrasound
jet velocity, CMR measurement of, 223–24
Kawasaki’s disease, 232
kilovoltage, 40
laboratory equipment, 336–37
Laplace relationship, 261
late gadolinium enhancement (LGE)
  CABG and, 171
  ischemic heart failure and, 171
  tissue characterization with, 170
left apical ballooning, 179
left atrial appendage
  CT for, 207
  thrombus in, 207
left ventricle (LV)
  architecture of, 170
  heart failure and, 169
  noncardiac surgery and, 186
left ventricular ejection fraction (LVEF)
dysfunction of
  CABG and, 111
  functional recovery and, 127–29
  histology of, 121
  prevalence of, 111
SPECT for, 115, 121
viability testing for, 112–13
  clinical interpretation of, 129–30
DE-CMR for, 115, 116, 117–18, 119, 121
  immediate levels of, 125–27
  myocardial function and, 113–14
  myocardial infarction in, 117–18
  myocardial metabolism and, 115, 117
  myocardial morphology and, 113
  myocardial perfusion and, 114
  scar tissue in, 124–25
  scintigraphic PET for, 115
  thin myocardium in, 122–24
Lenz effect, with implanted devices, 47
leukocyte adhesion molecules, 267
LGE see late gadolinium enhancement
lifetime risk calculators, 252
lipid-rich atheromatous plaque, 265
LV see left ventricle
LVEF see left ventricular ejection fraction
macrophage
  FDG and, 268
  glycolytic pathways and, 268
  infiltration, 144
  mononuclear phagocytes and, 267
  phagocytosis and, 267–68
  proteinase elaboration and, 268
  reactive oxygen species and, 269
magnetic gradients, 12
magnetic resonance coronary angiography (MRCA)
  CAD diagnosis with, 60, 61
  contraindications for, 70
  diagnostic accuracy of, 60
magnetic resonance imaging (MRI)
  for atherosclerosis, 85
  contrast agents for, 17–22
  coronary arteries and, 87
  aneurism of, 232
  anomalous, 232
  CABG and, 235–36
  contrast in, 231–32
  Kawasaki’s disease and, 232
  normal, 232
  operator experience in, 237
  plaques and, 237
  stenosis of, 233–35
  stents and, 236
  delayed-enhancement imaging in, 20
  display of, 16
  high field strength
    cardiac function and, 305–8
    challenges of, 305
    coronary imaging with, 310–12
    echo train of, 308
    flow assessment with, 312
    inversion recovery and, 307
    ischemia imaging with, 308–10
    myocardial infarction imaging with, 308–10
    myocardial perfusion imaging with, 310
    myocardial tagging with, 307
    parallel imaging with, 306
    signal to noise ration of, 305
    spatial resolution of, 305
methods for
  ECG-gated, 14
  magnetic gradients in, 12
  NMR phenomena of, 10–12
  phase-encoded, 13
  phase shift effects in, 14–15
  projection-reconstruction in, 12–13
  selective excitation in, 13–14
  time-of-flight effects in, 14
  motion artifact suppression by, 230–31
  protocol for, 15–16
  spatial resolution of, 229–30
  speed of, 15
  systems of, 15
  X-ray fused with, 341–42
magnetism, 44
magnetohydrodynamic effect, 305
manganese, 19, 300–301
matrix metalloproteinases, 261
MDCT see multidetector CT
medication
  adherence, 249
  provision of, 247–48
menopause, 247
meta analysis, with CAD, 151
microencapsulation, 280
microvascular obstruction, 299–300
molecular imaging
  hybrid imaging and, 144
  of plaque, 266
mononuclear phagocytes, 267
morbid events
  prediction of, 264
  after revascularization, 260
motion artifact suppression, 230–31
MRCA see magnetic resonance coronary angiography
MRI see magnetic resonance imaging
multidetector CT (MDCT)
  CAD diagnosis with, 58–60, 71–72
  contraindications for, 70
  contrast-enhanced, 58
  coronary calcium and, 58, 80–82
  diagnostic accuracy of, 59
  gantry rotation times of, 318–19
  introduction of, 318
  multiplanar images, 9
mutagenesis, 34
myocardial infarction
  "area at risk" with, 296
  chest pain and, 58
  CMR for, 295
  DE-CMR for, 20
  edema during, 298–99
  gadolinium with, 20
  LFEV dysfunction and, 117–18
  microvascular obstruction and, 299–300
  mortality rate of, 184
  MRI, high field strength, for, 308–10
  from noncardiac surgery, 184
  nonocclusive atheromata and, 261
  "no-reflow" phenomenon and, 299–300
  peri-infarct zone with, 296–98
  plaque disruption and, 261
  revascularization and, 299
  size of, 297
myocardial perfusion, 114
myocardial perfusion imaging
  with gadolinium, 19–20
  with high field strength MRI, 310
  limitations of, 158–59
  see also perfusion CMR
myocardial perfusion scintigraphy, 184
myocarditis, 175
myocardium
  function of, 113–14
  jeopardized, 160–61
  mechanics of
    DENSE and, 330, 331, 334
    heart disease and, 333
    MRI tagging with, 329–30
    strain in, 328–29
  metabolism of, 115, 117
  morphology of, 113
  necrosis of, 66
  thin, 122–24
  viability of, 173–74
myocytes, 175
necrosis, myocardial, 66
NMR see nuclear magnetic resonance
noise based CT, 40–41
"no-reflow" phenomenon, 299–300
normalcy rate, in CAD diagnosis, 151
nuclear magnetic resonance (NMR)
  chemical shift in, 11
  flip angle in, 10
  frequency in, 11
  spin echo in, 11
  spin in, 10
  steady-state free procession in, 11–12
nuclear spin, 10
ostial branch, 203
ostium, 203
pacemakers
for cardiac resynchronization, 211–12
CMR interactions with, 49, 50
permanent, 49
safety protocol for, 50
temporary, 49
parallel imaging, 306
paramagnetic contrast agents, 281
partial verification bias, 150
patient management
emergency room, 250
invasive testing and, 249–50
lifetime risk calculators and, 252
medication adherence and, 249
medication provision in, 247–48
noncalcified plaque and, 252
prognosis with, 251
valvular heart surgery and, 250
patient position, 7
PCI see percutaneous coronary intervention
percutaneous coronary intervention (PCI)
CAD, 96
revascularization with, 162
perfusion CMR
CAD diagnosis with, 64, 65, 66, 72
diagnostic accuracy of, 65
noncardiac surgery and, 189, 190
preoperative risk assessment with, 195
peri-infarct zone, 296–98
PET see positron emission tomography
phagocytes, mononuclear, 267
phagocytosis, 267–68
phase contrast velocity mapping, 221, 224
phase shift effects, 14–15
pitch control, automatic, 39–40
plaque
atherosclerosis imaging and, 245
coronary artery visualization and, 237
disruption of, 261
extracellular matrix of, 262
FDG uptake and, 144
fibrous skeleton of, 261
inflammation with, 263
lipid-rich atheromatous, 265
macrophage infiltration in, 144
molecular imaging of, 266
morphology of, 86–87
noncalcified, 252
quantification of, 85
sclerotic calcified, 265
stable, 262
stenosis and, 263–64
unstable, 262
platinum microcoils, 48
plexiform fibrosis, 176
positron emission tomography (PET)
adequacy of, 163
CAD diagnosis with, 149
diagnostic accuracy of, 149
hybrid imaging with, 136
LVEF viability testing with, 115
scintigraphic, 115
SPECT vs., 138
prediction
with coronary calcium, 264
of heart disease, 244
progressive interstitial fibrosis, 175
prosthetic valves, CMR interactions with, 47
proteinase elaboration, 268
pulmonary vein
anatomy of, 203–5
configurations of, 206
pulmonary vein stenosis
atrial fibrillation and, 207
CMR for, 207
quality evaluation process, 149
radiation see dose, radiation
radioactivity, 32
radionuclide ventriculography, 150
reactive oxygen species, 269
regurgitation
free pulmonary, 225
measurement of, 224
volume of, 224
reporter gene imaging, 279–80
resonance frequency, 11
resting function, 66
revascularization
anatomic data for, 161–62
atherosclerosis imaging and, 260
ischemic, 162
morbid events after, 260
myocardial infarction and, 299
PCI for, 162
prior CABG as, 100–102
prior stenting as, 102, 104–5
vein grafts as, 103
right ventricle (RV)
architecture of, 170
heart failure and, 169
risk
of adverse events, 152
area at, 296
CAD diagnosis and, 152–54
of CT dosage, 33–34
latent cardiovascular, 244
lifetime calculators of, 252
noncardiac surgery and, 184, 185
post-test
estimation of, 156
referral bias with, 157–58
reporting of, 156
preoperative assessment of, 194
stratification of, 151
test abnormalities and, 152–54
RV see right ventricle
saddle, 203
sarcoidosis, cardiac involvement in,
178–79
scar tissue, 124–25
sclerotic calcified plaque, 265
septal defect closure devices, CMR
interactions with, 48
shielding, bismuth-based breast, 40
shunt
pulmonary, 187
unrestricted, 188
signal to noise ratio, high field strength
MRI’s, 305
single photon emission computed
tomography (SPECT)
adecacy of, 163
adverse events after, 152
CAD diagnosis with, 149
diagnostic accuracy of, 149
hybrid imaging with, 136
LVEF viability testing with, 115,
121
PET vs., 138
smoking cessation, 245
SPAMM see spatial modulation of
magnetization
spatial modulation of magnetization
(SPAMM), 329
spatial resolution
of CT, 5, 323
of CTA, 229–30
of MRI, 229–30, 305
SPECT see single photon emission
computed tomography
spin echo, 11
statins, 270
steady-state free procession, 11–12
stem cell delivery, 283–84
stem cell imaging
case example of, 192
CMR for, 186
noncardiac surgery and, 186
stress ECG for, 186
arterial
atherosclerosis imaging and, 259–61
coronary, 233–35
degree of, 259
episodic occurrence of, 261
plaque and, 263–64
pulmonary vein
atrial fibrillation and, 207
CMR for, 207
stents
CMR interactions with, 47–48
coronary artery, 236
interventional CMR for, 339–40
as prior revascularization, 102, 104–5
stepwise approach
to CAD, 68–71
to noncardiac surgery risk assessment,
185
sterility, as radiation side effect, 34
sternal wires, CMR interactions with, 46
strain, 328–29
stress ECG
adverse events after, 152
for aortic stenosis, 186
limitations of, 158–59
noncardiac surgery risk assessment
with, 184
stress testing, treatment benefit
identification with, 155–56
superparamagnetic contrast agents, 281
surgery, noncardiac
myocardial infarction mortality rate
with, 184
noninvasive testing before
adult congenital heart disease and,
186, 188
aortic stenosis and, 186
CTA for, 189, 191
limitations of, 191
LV function and, 186
stress testing in, 188–89, 190
risk assessment with
myocardial perfusion scintigraphy
for, 184
stepwise approach to, 185
stress ECG for, 184
Swan-Genz catheters, 49
systole, 222, 319
tagging, myocardial, 307, 329–30
Tako-tsubo cardiomyopathy see left apical ballooning
technetium-99m, 158
temporal resolution, of CT, 5, 318–20
tetralogy of Fallot, 226
Thebesian valve, 213
thrombus, 207
through-plane velocity mapping, 227
time-of-flight effects, 14
“triple rule-out” protocol, 26
tube current modulation, 37, 38, 40
valve disease, 73
valve lesions, 226–27
valvular heart surgery, 250
vein
anterior interventricular, 213
conjoined, 203
coronary, 213
pulmonary
anatomy of, 203–5
configurations of, 206
vein grafts, 103
velocity mapping
phase contrast, 221, 224
through plane, 227
ventricular assist devices, CMR
stress interactions with, 51
visualization, 324
voxel, orientation of, 223
wires
epicardial, 46
guide, 48–49
sternal, 46
workstations, 324
X-ray, 341–42